bluebird bio Inc (NASDAQ:BLUE)’s share price hit a new 52-week low on Thursday after an insider sold shares in the company. The company traded as low as $100.99 and last traded at $111.96, with a volume of 21417 shares trading hands. The stock had previously closed at $113.65.

Specifically, insider David Davidson sold 5,000 shares of the firm’s stock in a transaction on Tuesday, October 2nd. The shares were sold at an average price of $139.32, for a total value of $696,600.00. Following the completion of the sale, the insider now directly owns 29,905 shares in the company, valued at $4,166,364.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director James Mandell sold 1,000 shares of the firm’s stock in a transaction on Monday, September 10th. The stock was sold at an average price of $150.77, for a total transaction of $150,770.00. Following the completion of the sale, the director now owns 1,568 shares of the company’s stock, valued at $236,407.36. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 21,490 shares of company stock valued at $2,901,186. 3.00% of the stock is currently owned by corporate insiders.

A number of equities research analysts have commented on BLUE shares. BidaskClub cut shares of bluebird bio from a “sell” rating to a “strong sell” rating in a report on Tuesday, October 23rd. Oppenheimer restated a “hold” rating on shares of bluebird bio in a report on Tuesday, November 27th. Goldman Sachs Group cut shares of bluebird bio from a “conviction-buy” rating to a “buy” rating in a report on Friday, September 21st. Morgan Stanley reduced their price target on shares of bluebird bio from $190.00 to $186.00 and set an “equal weight” rating for the company in a report on Monday, October 15th. Finally, Guggenheim initiated coverage on shares of bluebird bio in a report on Monday, September 17th. They issued a “neutral” rating for the company. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and seventeen have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $194.80.

The stock has a market capitalization of $6.22 billion, a P/E ratio of -14.12 and a beta of 2.37.

bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings data on Thursday, November 1st. The biotechnology company reported ($2.73) EPS for the quarter, topping the consensus estimate of ($2.90) by $0.17. The business had revenue of $11.50 million for the quarter, compared to analyst estimates of $6.90 million. bluebird bio had a negative net margin of 1,326.02% and a negative return on equity of 31.50%. The company’s revenue for the quarter was up 49.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.73) earnings per share. On average, analysts forecast that bluebird bio Inc will post -10.71 EPS for the current year.

A number of hedge funds have recently made changes to their positions in the business. FMR LLC raised its position in bluebird bio by 8.1% in the third quarter. FMR LLC now owns 8,123,687 shares of the biotechnology company’s stock worth $1,186,058,000 after acquiring an additional 605,797 shares during the period. Capital Research Global Investors raised its position in bluebird bio by 8.1% in the third quarter. Capital Research Global Investors now owns 6,634,317 shares of the biotechnology company’s stock worth $968,610,000 after acquiring an additional 494,787 shares during the period. Vanguard Group Inc. raised its position in bluebird bio by 10.1% in the third quarter. Vanguard Group Inc. now owns 4,619,413 shares of the biotechnology company’s stock worth $674,435,000 after acquiring an additional 422,866 shares during the period. Capital World Investors raised its position in bluebird bio by 37.4% in the third quarter. Capital World Investors now owns 3,425,687 shares of the biotechnology company’s stock worth $500,150,000 after acquiring an additional 931,932 shares during the period. Finally, Capital International Investors raised its position in bluebird bio by 188.6% in the third quarter. Capital International Investors now owns 3,260,636 shares of the biotechnology company’s stock worth $476,053,000 after acquiring an additional 2,130,927 shares during the period.

TRADEMARK VIOLATION WARNING: This report was published by Watch List News and is owned by of Watch List News. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at https://www.watchlistnews.com/bluebird-bio-blue-sets-new-12-month-low-on-insider-selling/2665987.html.

bluebird bio Company Profile (NASDAQ:BLUE)

bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.

See Also: What is dollar cost averaging (DCA)?

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.